[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587803":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":19,"responsibleParty":35,"collaborators":10,"id":37,"slug":10,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":10,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":22,"whyStopped":10,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"University Hospital, Tours","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients group",null,"The number of subjects required for our study was set at 30. It's a single-centre prospective non-interventional descriptive study. Patients will be followed every 3 months during 12 months. At inclusion, they will receive a first cycle of low-dose rituximab followed by a second cycle at 6 months.",[13],{"name":14,"role":15,"phone":16,"phoneExt":17,"email":18},"Simon BRUNET","CONTACT","247475917","+33","simon.brunet@chu-tours.fr",[20],{"facility":21,"status":22,"city":23,"state":10,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"University hospital","RECRUITING","Tours","37044","France","FR",{"type":28,"coordinates":29},"Point",[30,31],0.70398,47.39484,{"lat":31,"lon":30},[34],{"name":14,"role":15,"phone":16,"phoneExt":17,"email":18},{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100587803",false,"NCT06933134","Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis","PROLOD-RA","Inclusion Criteria:\n\n. Age ≥ 18 years\n\n* Diagnosis of rheumatoid arthritis meeting ACR\u002FEULAR 2010 criteria.\n* Candidates for a Low Dose regimen: on standard dose rituximab and with a good clinical response according to the referring rheumatologist. No maximum duration of use of standard-dose rituximab has been defined.\n* In the case of co-prescription of csDMARDs (Methotrexate, Leflunomide, Salazopyrine, Plaquenil), the dose must have been stable for 3 months.\n* If corticosteroids are co-prescribed, the dose should be ≤ 10 mg\u002Fd and stable for 3 months.\n\nExclusion Criteria:\n\n* Other associated targeted disease-modifying therapy\n* Sjögren's syndrome or other associated inflammatory rheumatism\n* Fibromyalgia or other pathology having an impact on the assessment of disease activity\n* Any active haematological disease affecting lymphocytes (chronic lymphocytic leukaemia, Hodgkin's and non-Hodgkin's lymphomas, lymphoplasmacytic lymphoma, T lymphoma).\n* Opposition to data processing\n* No inclusion of persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the Public Health Code (e.g. minors, protected adults, etc.).","ALL","18 Years",{"count":46,"type":47},30,"ESTIMATED","OBSERVATIONAL","Evaluation of the prediction of clinical response to rituximab at a dose of 1000 mg once using a pharmacological model including several pharmacokinetic and pharmacodynamic parameters.",[51],"Rheumatoid Arthritis (RA)",[53,54,55,56],"pharmacological biomarker","rituximab","retreatment","low dose","2026-04-29",{"date":59,"type":60},"2026-04-30","ACTUAL",{"date":62,"type":60},"2026-04-23",{"date":64,"type":47},"2028-11",{"name":5,"class":6},1]